North Carolina Biotechnology Center

BioAesthetics Welcomes Joseph Nixon to its Board of Directors

Retrieved on: 
Wednesday, August 23, 2023
Research, Other Health, Oncology, Consumer, Medical Devices, Surgery, Clinical Trials, Science, Biotechnology, Women, Stem Cells, Health, Other Science, Cleveland Clinic, Locus Biosciences, Quality of life, Case Western Reserve University, Locus, Corporation, Mastectomy, Novartis, Patient, Harvard Business School, Ideation, North Carolina Biotechnology Center, Burns, Cleveland, POP, Breast cancer, Pharmaceutical industry, Nursing, Alkermes, Biology

BioAesthetics Corporation announced today the appointment of Mr. Joseph Nixon to its Board of Directors.

Key Points: 
  • BioAesthetics Corporation announced today the appointment of Mr. Joseph Nixon to its Board of Directors.
  • Mr. Nixon brings over 25 years of life sciences investing and operating experience to BioAesthetics.
  • Nixon brings decades of experiences to BioAesthetics’ Board.
  • “I am excited and honored to join BioAesthetics as a Director,” said Mr. Nixon.

San Jacinto College and McCord Development to Partner on Biotechnology Training Center in Houston

Retrieved on: 
Tuesday, January 10, 2023
San Jacinto College, Southeastern United States, Ecosystem, Partnership, GMP, Greater Houston Partnership, Generation Park, McCord, Growth, Curriculum, Chancellor, North Carolina Biotechnology Center, Student, Medicine, Pharmaceutical industry

HOUSTON, Jan. 10, 2023 /PRNewswire/ -- San Jacinto College (San Jac) and McCord Development have signed a memorandum of understanding with the National Institute for Bioprocessing Research and Training (NIBRT) in Ireland for San Jacinto College to finalize definitive agreements to be the exclusive provider of NIBRT-licensed training programs in the southwestern and southeastern United States. The planned San Jacinto College Biotechnology Center, located in Generation Park, will train the captive local workforce and attract industry from across the country, helping to solidify Houston's role as a leading hub for life science manufacturing. Subject to definitive agreements based on industry feedback, San Jacinto College will be NIBRT's sixth global partner and second in the United States.

Key Points: 
  • HOUSTON, Jan. 10, 2023 /PRNewswire/ -- San Jacinto College (San Jac) and McCord Development have signed a memorandum of understanding with the National Institute for Bioprocessing Research and Training (NIBRT) in Ireland for San Jacinto College to finalize definitive agreements to be the exclusive provider of NIBRT-licensed training programs in the southwestern and southeastern United States.
  • Subject to definitive agreements based on industry feedback, San Jacinto College will be NIBRT's sixth global partner and second in the United States.
  • "We are thrilled to be in advanced discussions with San Jacinto College and McCord Development to bring our world-class training curriculum to Houston," said Darrin Morrissey, NIBRT's Chief Executive Officer.
  • "San Jacinto College's Biotechnology Center at Generation Park is the catalyst our region needs to fill the gap in our existing life science ecosystem and accelerate biomanufacturing in Houston," said Ryan McCord, President of McCord Development.

NIIMBL Pilots Biopharmaceutical Manufacturing Program to High School Students in North Carolina

Retrieved on: 
Tuesday, October 25, 2022
National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, Merck, U.S. Department of Commerce Office of Security, Commerce, NIST, Growth, Lilly, Sustainability, Navy, Office of Naval Research, Novartis Gene Therapies, Office, Program, Multimedia, Partnership, Student, Manufacturing USA, Industry, Health, Department, Awareness, Biologic, ONR, North Carolina Biotechnology Center, Department of the Navy Central Adjudication Facility, Fine chemical, Management, Pharmaceutical industry, Technology, Southern High School

NEWARK, Del., Oct. 25, 2022 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) launches NIIMBL bioLOGIC, a pilot program designed to bring awareness to and foster interest in careers in the biopharmaceutical manufacturing industry.

Key Points: 
  • NEWARK, Del., Oct. 25, 2022 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) launches NIIMBL bioLOGIC, a pilot program designed to bring awareness to and foster interest in careers in the biopharmaceutical manufacturing industry.
  • NIIMBL has partnered with the North Carolina Biotechnology Center and has selected Southern High School of Energy and Sustainability to pilot the 5-week program where students not only will learn and innovate but also will visualize themselves with a career in the industry.
  • By implementing the program at Southern High School of Energy and Sustainability, Black and Latinx high school students will have access to the biopharmaceutical manufacturing industry within their own community.
  • Following a successful pilot launch and expansion in North Carolina, NIIMBL looks forward to deploying the program in other regional ecosystems nationwide.

SUE W. COLE, FOUNDER AND MANAGING PARTNER OF SAGE LEADERSHIP & STRATEGY, ELECTED INCOMING CHAIR OF NACD BOARD OF DIRECTORS

Retrieved on: 
Wednesday, May 25, 2022
MBA, Education, North Carolina Biotechnology Center, Family, CA Technologies, Certification, National bank, McCracken, Leadership, Fortune 500, SAGE, North Carolina National Bank, Greater Greensboro Consortium, Martin Marietta Inc., University, NACD, Corporation, National Association of Corporate Directors, National Association, Greensboro Science Center, University of North Carolina School of the Arts, CEO, Management, Cole

WASHINGTON, May 25, 2022 /PRNewswire/ -- The National Association of Corporate Directors (NACD), the authority on boardroom practices representing more than 23,000 board members, today announced that Sue W. Cole has been elected chair of the NACD board of directors, effective May 25, 2022. She succeeds William "Bill" McCracken, a past CEO and board chair of CA Technologies, who was chair of the NACD Board. 

Key Points: 
  • WASHINGTON, May 25, 2022 /PRNewswire/ -- The National Association of Corporate Directors (NACD), the authority on boardroom practices representing more than 23,000 board members, today announced that Sue W. Cole has been elected chair of the NACD board of directors, effective May 25, 2022.
  • She succeeds William "Bill" McCracken, a past CEO and board chair of CA Technologies, who was chair of the NACD Board.
  • Cole is the founder and managing partner of SAGE Leadership & Strategy LLC, a boutique consultancy firm advising family and other private businesses as well as large nonprofits on strategy, leadership development, and governance.
  • She has more than 35 years of experience in the financial sector, including corporate lending and wealth management.

AGILE CITY ANNOUNCES WINNERS OF INNOVATION GRANTS

Retrieved on: 
Monday, January 10, 2022
Yamaha Aerox, Aviation, Patient, Technology, Cognition, Topical steroid withdrawal, EDGE, ADHD, Drink, Dairy Management Inc., Student, Mental health, Novant Health, Health, North Carolina Biotechnology Center, GA, DMI, Pain, Program, Music, MCU, Mentorship, Agriculture, Anatomical pathology, Communication, Emotion, Parrot, Energy, Medicine, Equilibrium

WINSTON-SALEM, N.C., Jan. 10, 2022 /PRNewswire/ -- Agile City , Winston-Salem, NC, a pioneer in the field of business ecosystem building and entrepreneur innovation, announced 9 winners of its Venture Winston Grants .

Key Points: 
  • WINSTON-SALEM, N.C., Jan. 10, 2022 /PRNewswire/ -- Agile City , Winston-Salem, NC, a pioneer in the field of business ecosystem building and entrepreneur innovation, announced 9 winners of its Venture Winston Grants .
  • Each company competed for a $50,000 non-dilutive and non-equity grant focusing on the future of nutrition and agriculture, health and wellbeing, and aviation and flight.
  • Grantees will be partnered with mentors from Dairy Management Inc. (DMI) , Novant Health and AeroX ,
    Winners have agreed to move51 percent of operations and a co-founder to Winston-Salem for one year beginning on January 31, 2022.
  • Other partners include Inmar Intelligence , Equilibrium , Greater Winston-Salem Inc. and the North Carolina Biotechnology Center .

URO-1 reaches key financial, product development and clinical milestones

Retrieved on: 
Tuesday, January 4, 2022
Time, Urology, Prostate cancer, Needle, Workflow, Pathology, Cancer, Goal, Overactive bladder, Prostate, Aggression, BOTOX, Disease, Biopsy, FDA, Woman, Achievement, Diagnosis, North Carolina Biotechnology Center, Man, Urogynecology, Workload, Death, Medical imaging, Medical device, Toxin (comics)

It also announced positive results from initial clinical studies of its FDA-cleared SUREcore biopsy needle and coreCARE specimen-retrieval kit for prostate biopsy.

Key Points: 
  • It also announced positive results from initial clinical studies of its FDA-cleared SUREcore biopsy needle and coreCARE specimen-retrieval kit for prostate biopsy.
  • One urologist told him, "If there ever was a procedure begging for innovation, it is prostate biopsy," Belleza said.
  • URO-1, established in 2017, is an emerging portfolio company of the North Carolina Biotechnology Center, www.ncbiotech.org , which in 2018 provided a $250,000 loan to support the company's early product development.
  • Clinical studies demonstrate that its use is associated with improved outcomes, increased patient comfort and reduced dropout rates for repeat treatment.

Jaguar Gene Therapy Announces State-of-the-Art Gene Therapy Commercial Manufacturing Facility in North Carolina

Retrieved on: 
Tuesday, October 26, 2021
Biotechnology, Diabetes, Health, Manufacturing, Other Health, Other Construction & Property, Commercial Building & Real Estate, Pharmaceutical, Construction & Property, Other Science, Research, Genetics, Science, Other Manufacturing, Safety, Commerce, CDMO, LinkedIn, Economic development, MBA, Partnership, Jaguar, Patient, Novartis Gene Therapies, Autism, GMP, Type 1, Control, CMC, North Carolina Community College System, LLC, Gene therapy, CEO, Lists of diseases, Galactosemia, Chemistry, North Carolina General Assembly, North Carolina Biotechnology Center, Pharmaceutical industry

Jaguar Gene Therapy , a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.

Key Points: 
  • Jaguar Gene Therapy , a company accelerating breakthroughs in gene therapy for larger patient populations suffering from severe genetic diseases, today announced plans for a commercial manufacturing facility in Durham, North Carolina.
  • At the commercial manufacturing facility in North Carolina, Jaguar plans to use the latest technologies and purification techniques to increase product yields while reducing product impurities.
  • Multiple organizations were valuable partners in supporting Jaguars expansion in North Carolina, including North Carolina Department of Commerce, Economic Development Partnership of North Carolina, North Carolina General Assembly, North Carolina Community College System, Durham County, Greater Durham Chamber of Commerce, North Carolina Biotechnology Center and Duke Energy.
  • Jaguar Gene Therapy, LLC is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases.

NoviSystems Launches Fusion Analytics Platform For Data-Driven Benefits In Health Care And Rare Disease Management, Drug Manufacturing

Retrieved on: 
Wednesday, October 20, 2021
Software, Biogen, Genentech, Caregiver, Intelligence, Institute, IBM, 2021 Essex County Council election, Rare disease, Data science, Microsoft Excel, Organization, Diagnosis, Pfizer, Marketing, North Carolina State University, Degenerative disease, Precision medicine, University Medical Center, Disease, Hospital, Research, Time, Hamner, ICD10, Natural language processing, Knowledge, Patient, Biotechnology, University, North Carolina Biotechnology Center, Compliance, Fusion, Lists of diseases, Physician, Daughtry, Wyeth, Government, Management, Information technology, Fine chemical, Medical imaging, Pharmaceutical industry

Anyone familiar with a pivot table in Microsoft's Excel software should be able to apply Fusion Analytics to their organizations.

Key Points: 
  • Anyone familiar with a pivot table in Microsoft's Excel software should be able to apply Fusion Analytics to their organizations.
  • Fusion Analytics is well suited for complex businesses in health care such as hospitals, biopharmaceutical and pharmaceutical manufacturers, and contract research organizations.
  • Daughtry is a past trustee of the Florida-based Phelan-McDermid Syndrome Foundation, a rare disease nonprofit organization, and a leading business consultant.
  • Since the inception of the Rare Disease InfoHub, leaders in the rare disease community like Daughtry have ensured that academic and commercial Fusion Analytics projects meet the needs of patients and families.

Advanced Chemotherapy Technologies, Inc. Awarded $4 Million NIH Grant to Pursue Treatment for Locally Advanced Non-resectable Pancreatic Cancer

Retrieved on: 
Thursday, August 12, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ACT, Emeritus, Neoplasm, Program, Translational medicine, Patient, University, Principal investigator, Laboratory, National, Sanjiv Sam Gambhir, SBIR, Pancreatic cancer, FDA, Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Multimedia, Toxicity, Health, NIH, Stanford University, Technology, Iontophoresis, University of North Carolina at Charlotte, University of North Carolina, North Carolina Biotechnology Center, Chemical engineering, National Cancer Institute, Pancreas, NCI, Pharmaceutical industry, Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials

The grant, in combination with prior financing, supports development of the companys ACT-IOP-003 local drug delivery system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.

Key Points: 
  • The grant, in combination with prior financing, supports development of the companys ACT-IOP-003 local drug delivery system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer.
  • View the full release here: https://www.businesswire.com/news/home/20210811005848/en/
    ACT-IOP-003 Pancreatic Cancer drug delivery system (Photo: Business Wire)
    Pancreatic cancer is a devastating disease with 5-year survival rates of only 10%.
  • New treatment modalities are desperately needed and ACT is developing the ACT-IOP-003 system for the targeted delivery of the FDA-approved chemotherapy treatment gemcitabine.
  • Advanced Chemotherapy Technologies, Inc. is a privately owned, clinical-stage company developing novel approaches to local drug delivery.

FUJIFILM Diosynth Biotechnologies Expands Its North Carolina Facility Cell Culture And Microbial Capacity

Retrieved on: 
Tuesday, February 25, 2020
Diosynth, Oss, Fujifilm, North Carolina Biotechnology Center, Morrisville, Optics, Companies, Economy of Japan

The 31,778 square foot addition includes the expansion of its cell culture and microbial manufacturing trains through the addition of new recover and purification suites.

Key Points: 
  • The 31,778 square foot addition includes the expansion of its cell culture and microbial manufacturing trains through the addition of new recover and purification suites.
  • The North Carolina site will increase its cell culture manufacturing capacity by approximately 25% and microbial capacity by approximately 50%.
  • The event was attended by representatives from local organizations including Economic Development of North Carolina, The RTP Foundation, North Carolina Biosciences Organization, North Carolina Biotechnology Center and the Morrisville Chamber of Commerce among others.
  • FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.